Lonza Group AG (SWX: LONN)

https://www.lonza.com

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector. Founded in 1897 in the Swiss Alps, today Lonza operates acrossfive continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com *

	Start	1999-11-01 splitoff
	Group	Lonza (Group)
	Today	Lonza (Group)
	Industry	contract manufacturing (biologicals)
	Person	Ruffieux, Pierre-Alain (Lonza 202011– CEO before Roche + Novartis + Serono)
	Person 2	Savitzky, Rodolfo (Lonza 201801 CFO)

	Region	Basel BS
	Country	Switzerland
	Street	38 Münchensteiner Str.
	City	4002 Basel BS
	Tel	+41-61-316-8111
		Address record changed: 2024-01-05

Basic data	Employees	H: 10,001 to 50,00 (2022-03-23)
	Currency	CHF
	Annual sales	5,400,000,000 (sales, consolidated (2021) 2021-12-31)

		* Document for »About Section«: Lonza Group AG. (5/6/21). "Press Release: Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)". Basel.

		Record changed: 2024-04-02